A complete research library on TB-500 — the synthetic 7-amino-acid fragment of Thymosin Beta-4 (sequence LKKTETQ) that promotes healing through actin cytoskeleton remodeling and cell migration. Real mechanism of action, published research, dosage protocols, side effect profiles, the BPC-157 healing stack, and the 2026 regulatory landscape after FDA Category 2 removal.
TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein expressed in virtually every human cell that plays a central role in cell migration, wound healing, and tissue repair. The name “TB-500” refers specifically to the 7-amino-acid fragment with the sequence LKKTETQ — the region of Thymosin Beta-4 responsible for its actin-binding and cell-migration-promoting activity. When researchers and clinicians refer to “TB-500 peptide” or “TB4 peptide,” they are referencing this synthetic fragment rather than the full-length Thymosin Beta-4 protein, though the terms are frequently used interchangeably in the peptide therapy community. You may also encounter variations like “TB4 frag,” “thymosin b4,” and “thymosin 4” — all referring to the same peptide or its parent protein.
Thymosin Beta-4 was first isolated from the thymus gland in the 1960s by Allan Goldstein at the National Institutes of Health. The protein’s role in actin cytoskeleton dynamics — specifically its ability to sequester G-actin monomers and regulate the polymerization of actin filaments — was established through subsequent decades of research. The critical insight was that the LKKTETQ region of Tβ4 is the minimum active fragment needed to promote cell migration: when cells are exposed to this sequence, they upregulate migration machinery, accelerate wound closure in scratch assays, and increase angiogenesis in tissue models. This is the biological rationale for the TB-500 peptide (also written TB 500 peptide or TB500 peptide) as a healing peptide — it recapitulates the migration-promoting activity of the full-length thymosin beta 4 protein in a smaller, more easily synthesized and administered form.
Unlike peptides that operate through receptor binding (the way BPC-157 interacts with the VEGFR2 pathway, for instance), TB-500 works intracellularly. It enters the cell, binds actin, and modulates the cytoskeletal dynamics that control cell movement. This intracellular mechanism is why TB-500 has systemic effects despite subcutaneous injection — the peptide distributes through tissue and acts on cells it contacts directly rather than requiring specific receptor expression at the injection site. It is also why TB-500 has been investigated for such a broad range of healing applications: tendons, ligaments, muscles, cardiac tissue, skin, and even hair follicle activation all depend on cell migration for repair, and TB-500 promotes the underlying migration machinery in all of them.
The TB-500 peptide research base includes a completed Phase 1 human clinical trial (PMID 34346165) confirming safety and tolerability in human subjects, extensive preclinical work in cardiac repair following myocardial infarction, tendon and ligament healing, muscle injury recovery, corneal wound healing, and hair regrowth through the thymosin beta-4 pathway. Among peptide therapy practitioners, TB-500 occupies the role of a systemic healing peptide — often stacked with BPC-157 for combined local and systemic tissue repair coverage. The TB-500 and BPC-157 stack page covers this combination in detail.
Mechanism and molecular biology, healing applications from tendon repair to hair follicles, the BPC-157 synergy stack, side effect data, injection protocols, and what the 2026 regulatory changes actually mean — all built from published research rather than supplement marketing copy.
Actin cytoskeleton remodeling, cell migration promotion, the healing cascade from tendons to cardiac tissue, hair growth via the thymosin beta-4 pathway, and which effects have clinical evidence versus preclinical data only.
Read page →Phase 1 human safety data, reported adverse effects, the cancer concern that dominated early literature, WADA prohibition status, and the open questions that remain about long-term use.
Read page →Loading and maintenance phase dosing, cycle length considerations, TB-500 half-life pharmacokinetics, reconstitution math for 2 mg and 5 mg vials, bodybuilding protocols, and dosage for injury recovery.
Read page →Why the TB-500 + BPC-157 combination is the most widely used peptide healing stack. Dosage protocols, blend ratios, mechanism synergy (systemic migration + local angiogenesis), and comparison of individual versus stacked outcomes.
Read page →Where to inject TB-500, subcutaneous technique, reconstitution and mixing instructions, injection site selection, insulin syringe basics, and step-by-step preparation from lyophilized vial to injection.
Read page →Research-grade peptide pricing, compounding pharmacy costs, clinic protocol pricing, cost per cycle at various dosing protocols, and what to look for when evaluating peptide quality and sourcing.
Read page →Realistic timelines by injury type — tendon, ligament, muscle, post-surgical — what to expect at 2, 4, 8, and 12 weeks, how to measure progress, and why anecdotal reports vary so widely.
Read page →Head-to-head mechanism comparison, tissue-specific strengths, when to use one versus both, side effect profile differences, and the research that supports combining them for injury recovery.
Read page →| Origin | TB-500 is a synthetic reproduction of the active region (sequence LKKTETQ) of Thymosin Beta-4, a 43-amino-acid protein first isolated from bovine thymus tissue by Allan Goldstein’s lab at the National Institutes of Health in the 1960s. The parent protein Tβ4 is one of the most abundant intracellular peptides in mammalian cells, found in nearly every tissue type. The synthetic TB-500 fragment was developed to isolate and deliver the cell-migration-promoting activity without requiring the full-length protein. |
|---|---|
| Mechanism | TB-500 promotes healing through actin cytoskeleton remodeling. It binds G-actin monomers, preventing premature polymerization and allowing cells to reorganize their internal scaffolding for directed migration. This upregulates cell migration to injury sites, promotes angiogenesis (new blood vessel formation), reduces inflammation through cytokine modulation, and accelerates extracellular matrix deposition. The mechanism is intracellular and systemic — TB-500 does not require a specific surface receptor, which is why it affects healing across such diverse tissue types including muscle, tendon, ligament, skin, and cardiac tissue. |
| Clinical status | A Phase 1 human clinical trial (PMID 34346165) has been completed, confirming safety and tolerability at therapeutic doses. Extensive preclinical data exists for cardiac repair post-myocardial infarction, corneal wound healing, dermal wound closure, tendon/ligament repair, and hair regrowth. TB-500 has a long history of veterinary use in equine medicine for tendon and ligament injuries, which generated much of the early safety and efficacy signal. No Phase 2 or Phase 3 human trials have been completed as of 2026. |
| Regulatory status | TB-500 was placed on the FDA Category 2 bulk drug substances list in 2023, restricting compounding pharmacy preparation. On April 15, 2026, HHS removed TB-500 from Category 2, effective April 22, 2026, removing the enforcement basis for the compounding restriction. TB-500 has not yet been placed on the Category 1 bulks list — the PCAC meeting scheduled for July 23–24, 2026 will review peptides including TB-500 for potential 503A compounding authorization. TB-500 is prohibited in competition by WADA under S2 (Peptide Hormones). It was previously widely compounded and prescribed by peptide therapy clinics before the 2023 Category 2 restriction. |
| The BPC-157 stack | TB-500 and BPC-157 are the two most commonly combined healing peptides. The rationale: TB-500 provides systemic cell migration support (getting repair cells to the injury site) while BPC-157 provides local angiogenesis and tissue-specific repair signaling (building the blood supply and signaling matrix at the injury site). Different mechanisms, complementary coverage, additive healing outcomes in community practice. The dedicated stack page covers protocols, dosing, and the published research behind the combination. |